Abstract
MUTYH-associated polyposis (MAP) is an autosomal recessive predisposition to colorectal cancer (CRC) and intestinal polyposis, representing less than 1 % of CRC cases. This condition is characterized by the development of between 10 and 100 colorectal polyps and presents diagnostic challenges due to its phenotypic overlap with other hereditary CRC syndromes, including Lynch syndrome and attenuated familial adenomatous polyposis. This chapter provides a detailed description of MAP, including its clinical characteristics and molecular genetics, as well as implications for affected patients and families including inheritance, genetic testing, surveillance, and preventive recommendations. A proposed algorithm for MUTYH genetic testing is also provided for this important, but rare, hereditary predisposition to CRC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet. 2002;30(2):227–32.
Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology. 2009;136(4):1251–60.
Nielsen M, Joerink-van de Beld MC, Jones N, Vogt S, Tops CM, Vasen HF, et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology. 2009;136(2):471–6.
Aretz S, Uhlhaas S, Goergens H, Siberg K, Vogel M, Pagenstecher C, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer. 2006;119(4):807–14.
Landon M, Ceulemans S, Saraiya DS, Strike B, Arnell C, Burbidge LA, et al. Analysis of current testing practices for biallelic MUTYH mutations in MUTYH-associated polyposis. Clin Genet. 2015;87(4):368–72.
Guarinos C, Sanchez-Fortun C, Rodriguez-Soler M, Alenda C, Paya A, Jover R. Serrated polyposis syndrome: molecular, pathological and clinical aspects. World J Gastroenterol. 2012;18(20):2452–61.
Guarinos C, Juarez M, Egoavil C, Rodriguez-Soler M, Perez-Carbonell L, Salas R, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res. 2014;20(5):1158–68.
Boparai KS, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology. 2008;135(6):2014–8. Epub 2008/11/18.
Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137(6):1976–85 e1-10.
Guillen-Ponce C, Castillejo A, Barbera VM, Pascual-Ramirez JC, Andrada E, Castillejo MI, et al. Biallelic MYH germline mutations as cause of Muir-Torre syndrome. Fam Cancer. 2010;9(2):151–4. Epub 2009/12/10.
Morak M, Heidenreich B, Keller G, Hampel H, Laner A, de la Chapelle A, et al. Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum Genet. 2014;22(11):1334–7.
David SS, O’Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature. 2007;447(7147):941–50. Epub 2007/06/22.
Lipton L, Tomlinson I. The genetics of FAP and FAP-like syndromes. Fam Cancer. 2006;5(3):221–6. Epub 2006/09/26.
Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A. Working Group of the American College of Medical G, et al. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med. 2014;16(1):101–16.
Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol. 2011;79(1):1–16.
Rouleau E, Zattara H, Lefol C, Noguchi T, Briaux A, Buecher B, et al. First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome. Clin Genet. 2011;80(3):301–3.
Borras E, Taggart MW, Lynch PM, Vilar E. Establishing a diagnostic road map for MUTYH-associated polyposis. Clin Cancer Res. 2014;20(5):1061–3.
Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat. 1994;3(2):121–5.
Castillejo A, Vargas G, Castillejo MI, Navarro M, Barbera VM, Gonzalez S, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer. 2014;50(13):2241–50.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessment: Colorectal. National Comprehensive Cancer Network. 2014.
Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4(5):655–65. Epub 2011/05/06.
Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346(14):1054–9. Epub 2002/04/05.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946–52. Epub 2000/06/30.
Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010;105(6):1437–43. Epub 2010/03/18.
Sturgeon D, Herline AJ, Wise PE. Do NSAIDs suppress polyps in MUTYH-associated polyposis? A case report. Hered Cancer Clin Pr. 2011;9(Suppl 1):36.
Frattini M, Carnevali I, Signoroni S, Balestra D, Moiraghi ML, Radice P, et al. Cyclooxygenase-2 expression in FAP patients carrying germ line MYH mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(8):2049–52. Epub 2005/08/17.
Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology. 2009;137(2):489–94, 94 e1; quiz 725–6.
Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology. 2014;146(5):1208–11 e1–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mork, M.E., Vilar, E. (2016). MUTYH-Associated Polyposis. In: Boardman, L. (eds) Intestinal Polyposis Syndromes. Springer, Cham. https://doi.org/10.1007/978-3-319-28103-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-28103-2_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28101-8
Online ISBN: 978-3-319-28103-2
eBook Packages: MedicineMedicine (R0)